The goals of this proposal are to translate immunologic discoveries from Dr. Carson's laboratory into clinical trials for cancer patients and to use this research program as a means of training young physicians in patient-oriented research. Some of the most exciting new anti-cancer therapies are based on immunologic discoveries. Recombinant cytokines and monoclonal antibodies are now routinely used to treat cancer patients. Dr. Carson's clinical program has focused on two specific areas of investigation: 1). The use of immunostimulatory compounds to augment the immune response to therapeutic anti-tumor monoclonal antibodies, and 2). The use of cytokines alone or in combination with targeted agents to treat patients with metastatic melanoma. The majority of the trials presented here have evolved from basic experimental observations that were made in Dr. Carson's immunology laboratory. Dr. Carson's trials are unique in that they incorporate a series of in-depth correlative studies designed to evaluate the effects of the treatment regimen on the activity of the patient's immune system and the growth of the patient's tumor. These laboratory studies have permitted a rational evaluation of the immunotherapeutic regimens and have guided the development of subsequent trials. In addition, they have allowed Dr. Carson to attract funding for his clinical research from the NCI and other extramural sources. In conjunction with these clinical activities, Dr. Carson has developed a systematic training program in patient-oriented research for young investigators. A number of Medical and Surgical Oncology Fellows, surgical residents, and early career Assistant Professors at the Ohio State University Comprehensive Cancer Center have participated in the development and conduct of Dr. Carson's clinical trials. The goal of this program is to teach participants how to generate and administer protocols of their own design via direct patient interaction and specialized tutorial sessions. Trainees will also attend a series of oncologic didactic sessions and meet regularly with Dr. Carson to discuss their patients and their educational experiences. Dr. Carson's role as national P.I. on a randomized trial of chemotherapy with or without an anti-angiogenic drug (bevacizumab, Avastin(tm)) insures that trainees will also gain valuable experience in this aspect of clinical research. Finally, a special emphasis has been placed on instruction relating to the ethical conduct of patient-oriented research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Schools of Medicine
United States
Zip Code
Wu, Salene M; Yang, Hae-Chung; Thayer, Julian F et al. (2014) Association of the physiological stress response with depressive symptoms in patients with breast cancer. Psychosom Med 76:252-6
Markowitz, Joseph; Luedke, Eric A; Grignol, Valerie P et al. (2014) A phase I trial of bortezomib and interferon-*-2b in metastatic melanoma. J Immunother 37:55-62
Varker, Kimberly A; Ansel, Adam; Aukerman, Glen et al. (2012) Review of complementary and alternative medicine and selected nutraceuticals: background for a pilot study on nutrigenomic intervention in patients with advanced cancer. Altern Ther Health Med 18:26-34
Mundy-Bosse, Bethany L; Lesinski, Gregory B; Jaime-Ramirez, Alena C et al. (2011) Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 71:5101-10
Guenterberg, Kristan D; Grignol, Valerie P; Relekar, Kiran V et al. (2011) A pilot study of bevacizumab and interferon-*2b in ocular melanoma. Am J Clin Oncol 34:87-91
Mundy-Bosse, Bethany L; Young, Gregory S; Bauer, Todd et al. (2011) Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4? T cells from patients with GI malignancy. Cancer Immunol Immunother 60:1269-79
Jaime-Ramirez, Alena Cristina; Mundy-Bosse, Bethany L; Kondadasula, SriVidya et al. (2011) IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-ýý production. J Immunol 186:3401-9
Grignol, Valerie P; Olencki, Thomas; Relekar, Kiran et al. (2011) A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother 34:509-15
Mundy-Bosse, Bethany L; Thornton, Lisa M; Yang, Hae-Chung et al. (2011) Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol 270:80-7
Guenterberg, Kristan D; Lesinski, Gregory B; Mundy-Bosse, Bethany L et al. (2011) Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4ýýý and CD8ýýý T cells. Cancer Immunol Immunother 60:1281-8

Showing the most recent 10 out of 29 publications